Skip to content

To determine direct cost, drug utilization, and complications in Covid-19 positive pediatric population

COVID-19 Complications, Treatment, Outcomes and Cost in Pediatric Population

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/01/039676
Enrollment
176
Registered
2022-01-25
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Pediatric inpatients of both gender Age less than 18 yrs. (As per the National Commission for Protection of Child Rights, a child is defined as a person from 0 to 18 years of age irrespective of their gender) Symptomatic patients Pediatric patients with evidence of recent COVID-19 infection (RT-PCR positive), or likely contact with patients with COVID-19 Pediatric patients diagnosed with MIS-C

Exclusion criteria

Exclusion criteria: Patients who are on alternative system of medicine such as Ayurveda system Patients with missing RT-PCR positive report of insufficient medical data

Design outcomes

Primary

MeasureTime frame
Data on demographic features and treatment aspects of pediatric COVID-19 patients.Timepoint: 24 weeks

Secondary

MeasureTime frame
Length of hospital stay, utilization of intensive care, and financial burden of hospitalization.Timepoint: 24 Weeks

Countries

India

Contacts

Public ContactFemida Rashid

Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education

nair.sreedhar@manipal.edu9844545682

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026